Bluebird bio opens a state-of-the art gene and cell therapy manufacturing facility in Durham, NC

Governor Cooper to cut ribbon on bluebird bio facility

Bluebird bio (BLUE) announced today, in its press release, the official opening of its first wholly owned manufacturing facility in Durham, N.C. The new facility will produce the lentiviral vector for the company’s investigational gene and cell therapies, including bb2121 and bb21217 for the treatment of multiple myeloma, and potentially LentiGlobin™ for transfusion-dependent β-thalassemia (TDT) and sickle cell disease.

Gov. Roy Cooper, Secretary of Commerce Tony Copeland and local patient advocates will join chief bluebird Nick Leschly in . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.